# To Evaluate The Effects Of SB-649868 (10, 30 Mg And 60 Mg) On Subjects With Primary Insomnia

> **NCT00426816** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 48 (actual)

## Conditions studied

- Sleep Initiation and Maintenance Disorders

## Interventions

- **DRUG:** SB-649868
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00426816
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2012-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00426816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00426816, "To Evaluate The Effects Of SB-649868 (10, 30 Mg And 60 Mg) On Subjects With Primary Insomnia". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00426816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*